Literature DB >> 8083382

Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.

R Morishita1, G H Gibbons, K E Ellison, W Lee, L Zhang, H Yu, Y Kaneda, T Ogihara, V J Dzau.   

Abstract

In vitro studies have demonstrated that angiotensin (Ang) II directly stimulates vascular smooth muscle cell (VSMC) growth. However, it is still unclear if Ang II exerts a direct effect on vascular hypertrophy in vivo independent of its effect on blood pressure. In vivo gene transfer provides the opportunity to assess the effects of increased activity of the vascular angiotensin system in the intact animal while avoiding an increase in circulating angiotensin or in blood pressure. Accordingly, we transfected the human angiotensin converting enzyme (ACE) vector into intact rat carotid arteries by the hemagglutinating virus of Japan-liposome method. 3 d after transfection, we detected increased ACE activity in the transfected artery. Immunohistochemistry localized immunoreactive ACE in the medial VSMC as well as in the intimal endothelial cells. The increase in vascular ACE activity was associated with a parallel increase in DNA synthesis as assessed by BrdU (bromo-deoxyuridine) index and vascular DNA content. This increase in DNA synthesis was abolished by the in vivo administration of an Ang II receptor-specific antagonist (DuP 753). Morphometry at 2 wk after transfection revealed an increase in the wall to lumen ratio of the ACE-transfected blood vessel as compared with control vector transfected vessels. This was accompanied by increases in protein and DNA contents without an increase in cell number. Local transfection of ACE vector did not result in systemic effects such as increased blood pressure, heart rate, or serum ACE activity. These morphological changes were abolished by the administration of the Ang II receptor antagonist. In this study, we used in vivo gene transfer to increase local expression of vascular angiotensin converting enzyme and provided proof that increased autocrine/paracrine angiotensin can directly cause vascular hypertrophy independent of systemic factors and hemodynamic effects. This approach has important potentials for defining the role of autocrine/paracrine substances in vascular biology and hypertension.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083382      PMCID: PMC295142          DOI: 10.1172/JCI117464

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Increased expression of DNA cointroduced with nuclear protein in adult rat liver.

Authors:  Y Kaneda; K Iwai; T Uchida
Journal:  Science       Date:  1989-01-20       Impact factor: 47.728

2.  Cellular hypertrophy in mesenteric resistance vessels from renal hypertensive rats.

Authors:  N Korsgaard; M J Mulvany
Journal:  Hypertension       Date:  1988-08       Impact factor: 10.190

3.  Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning.

Authors:  F Soubrier; F Alhenc-Gelas; C Hubert; J Allegrini; M John; G Tregear; P Corvol
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

Review 5.  The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system.

Authors:  M Paul; D Ganten
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

6.  Novel and effective gene transfer technique for study of vascular renin angiotensin system.

Authors:  R Morishita; G H Gibbons; Y Kaneda; T Ogihara; V J Dzau
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 7.  The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes.

Authors:  V J Dzau
Journal:  Curr Opin Nephrol Hypertens       Date:  1993-01       Impact factor: 2.894

8.  Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.

Authors:  A A Geisterfer; M J Peach; G K Owens
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

9.  Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension.

Authors:  B I Levy; J B Michel; J L Salzmann; M Azizi; P Poitevin; M Safar; J P Camilleri
Journal:  Circ Res       Date:  1988-07       Impact factor: 17.367

10.  Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells.

Authors:  G K Owens; A A Geisterfer; Y W Yang; A Komoriya
Journal:  J Cell Biol       Date:  1988-08       Impact factor: 10.539

View more
  25 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

2.  Meta-analysis of the ACE gene in ischaemic stroke.

Authors:  P Sharma
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

3.  Effects of angiotensin I and angiotensin II in blood vessels: greater influence of converting enzyme activity in the rabbit basilar artery.

Authors:  A Zerrouk; M Auguet; S Delaflotte; P E Chabrier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 4.  Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.

Authors:  M E Cooper; D Vranes; J R Rumble
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

5.  Cell signaling, internalization, and nuclear localization of the angiotensin converting enzyme in smooth muscle and endothelial cells.

Authors:  Héctor A Lucero; Ekaterina Kintsurashvili; Maria E Marketou; Haralambos Gavras
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

Review 6.  Gene therapy for vein grafts.

Authors:  M J Mann
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

7.  Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits.

Authors:  H Mitani; T Bandoh; J Ishikawa; M Kimura; T Totsuka; S Hayashi
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 8.  Clinical achievements of impedance analysis.

Authors:  Gary F Mitchell
Journal:  Med Biol Eng Comput       Date:  2008-10-14       Impact factor: 2.602

9.  Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy.

Authors:  Xiangbin Xu; Chang-Hoon Ha; Chelsea Wong; Weiye Wang; Angelika Hausser; Klaus Pfizenmaier; Eric N Olson; Timothy A McKinsey; Zheng-Gen Jin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-06       Impact factor: 8.311

10.  Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.

Authors:  Gary F Mitchell; Mark E Dunlap; Wayne Warnica; Anique Ducharme; J Malcolm O Arnold; Jean-Claude Tardif; Scott D Solomon; Michael J Domanski; Kathleen A Jablonski; Madeline M Rice; Marc A Pfeffer
Journal:  Hypertension       Date:  2007-04-23       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.